{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:09:10Z","timestamp":1788930550688,"version":"build-2803163510"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of neoadjuvant PD-1 inhibitor combined with chemotherapy (nab-paclitaxel + cisplatin) in patients with locally advanced hypopharyngeal squamous cell carcinoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted on 75 patients with locally advanced (stage III-IVA) hypopharyngeal cancer diagnosed at the First Affiliated Hospital of Xiamen University between January 2021 and May 2023. All patients received at least 2 cycles of neoadjuvant immunochemotherapy followed by radical surgery and adjuvant radiotherapy. Objective response rate (ORR), major pathological response (MPR), pathological complete response (pCR), larynx-preserving surgery rate, progression-free survival (PFS), and safety were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 75 patients, the ORR was 77.3% (58\/75), MPR rate was 78.7% (59\/75), standard pCR rate (primary + lymph nodes) was 17.3% (13\/75), primary tumor pCR rate was 26.7% (20\/75), and larynx-preserving surgery rate was 86.7% (65\/75). With a median follow-up of 26 months, the 12-month and 24-month overall survival rates were 93.3% and 76.0%, respectively, and the PFS rates were 92.0% and 76.0%, respectively. The MPR group demonstrated significantly superior PFS compared to the non-MPR group (HR\u00a0=\u00a00.052, 95% CI: 0.019-0.140,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001), with 24-month PFS rates of 89.7% and 12.5%, respectively. The ORR group also showed significantly superior PFS compared to the non-ORR group (HR\u00a0=\u00a00.29, 95% CI: 0.13-0.66,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.003), with 24-month PFS rates of 86.2% and 41.2%, respectively. Concordance between radiological and pathological assessments was moderate (\u03ba=0.417,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.001). The safety profile was favorable, with no grade 3\u20135 treatment-related adverse events observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Neoadjuvant PD-1 inhibitor combined with chemotherapy induces significant radiological and pathological responses in patients with locally advanced hypopharyngeal cancer, effectively improving larynx-preserving surgery rate and progression-free survival with a favorable safety profile. Pathological assessment (particularly MPR) may provide complementary prognostic information to radiological assessment.This regimen demonstrates promising short-term efficacy and larynx preservation benefits, warranting further prospective validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1928173","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:40:50Z","timestamp":1788928850000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of neoadjuvant immune checkpoint inhibitors combined with chemotherapy in locally advanced hypopharyngeal squamous cell carcinoma: a retrospective analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Xueying","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital of Xiamen University","place":["Xiamen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linteng","family":"Chen","sequence":"additional","affiliation":[{"name":"Xiamen Humanity Hospital, Department of Gastroenterology","place":["Xiamen, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiming","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital of Xiamen University","place":["Xiamen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-Yang","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital of Xiamen University","place":["Xiamen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0282603","article-title":"Updated racial disparities in incidence, clinicopathological features and prognosis of hypopharyngeal squamous carcinoma in the United States","volume":"18","author":"Liang","year":"2023","journal-title":"PloS One"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/lary.24915","article-title":"Survival trends in hypopharyngeal cancer: a population-based review","volume":"125","author":"Newman","year":"2015","journal-title":"Laryngoscope"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.17305\/bb.2023.8978","article-title":"Developing a predictive nomogram and web-based survival calculator for locally advanced hypopharyngeal cancer: A propensity score-adjusted, population-based study","volume":"23","author":"Chen","year":"2023","journal-title":"Biomol BioMed"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/lary.29857","article-title":"Health-related quality of life, dysphagia, voice problems, depression, and anxiety after total laryngectomy","volume":"132","author":"Wulff","year":"2022","journal-title":"Laryngoscope"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002485","article-title":"Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma","volume":"9","author":"Leidner","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.12.032","article-title":"Emerging role of ubiquitination in the regulation of PD-1\/PD-L1 in cancer immunotherapy","volume":"29","author":"Hu","year":"2021","journal-title":"Mol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2019.02.007","article-title":"Immune evasion by head and neck cancer: foundations for combination therapy","volume":"5","author":"Horton","year":"2019","journal-title":"Trends Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/jco.21.02508","article-title":"Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study","volume":"41","author":"Harrington","year":"2023","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/nejmoa2415434","article-title":"Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer","volume":"393","author":"Uppaluri","year":"2025","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/hed.21613","article-title":"Current trends in initial management of hypopharyngeal cancer: the declining use of open surgery","volume":"34","author":"Takes","year":"2012","journal-title":"Head Neck"},{"key":"B13","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3390\/jpm14080817","article-title":"Quality of life of patients using esophageal speech after total laryngectomy: A systematic review study","volume":"14","author":"Plotas","year":"2024","journal-title":"J Pers Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/hed.21022","article-title":"National Cancer Database report on cancer of the head and neck: 10-year update","volume":"31","author":"Cooper","year":"2009","journal-title":"Head Neck"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.43.6097","article-title":"Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer","volume":"31","author":"Forastiere","year":"2013","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1007\/s10637-024-01456-w","article-title":"Neoadjuvant immunochemotherapy in locally advanced laryngeal cancer and hypopharyngeal cancer: higher objective response rate and organ-preservation rate","volume":"42","author":"Chen","year":"2024","journal-title":"Invest New Drugs"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/hed.27119","article-title":"Induction chemotherapy of modified docetaxel, cisplatin, 5-fluorouracil for laryngeal preservation in locally advanced hypopharyngeal squamous cell carcinoma","volume":"44","author":"Li","year":"2022","journal-title":"Head Neck"},{"key":"B18","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1093\/jnci\/djp202","article-title":"Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation","volume":"101","author":"Pointreau","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1466310","article-title":"Comparison of the efficacy and safety of neoadjuvant PD-1 inhibitors plus chemotherapy vs targeted therapy plus chemotherapy in locally advanced hypopharyngeal squamous cell carcinoma","volume":"15","author":"Gao","year":"2024","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1585194","article-title":"Effective imaging examination evaluation method for surgical pathological complete responds of head and neck squamous cell carcinoma after neoadjuvant immunochemotherapy","volume":"15","author":"Ning","year":"2025","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5434","article-title":"Biomarkers predictive of response to pembrolizumab in head and neck cancer","volume":"12","author":"Pfister","year":"2023","journal-title":"Cancer Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"107151","DOI":"10.1016\/j.oraloncology.2024.107151","article-title":"The characterization of tumor immune microenvironment after neoadjuvant immunotherapy in head and neck squamous cell cancer using multiplex immunohistochemistry","volume":"161","author":"An","year":"2025","journal-title":"Oral Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1928173\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:41:00Z","timestamp":1788928860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1928173\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":22,"alternative-id":["10.3389\/fonc.2026.1928173"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1928173","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1928173"}}